Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Jennifer Gudeman's publication output changed over time?
ScholarIQpublication output · 2022–2025
Output grew200% over the shown period — from 1 works in 2022 to 3 in 2025.
1
4
4
3
2022202320242025
What are the most-cited papers on Jennifer Gudeman?
ScholarIQmost cited works
Demographic characteristics and comorbidities of patients with narcolepsy: a propensity-matched cohort study
Melissa C. Lipford, Wui Ip, Samir Awasthi, James L. Moore, Maja Tippmann‐Peikert, Shahir Asfahan, Praveen Kumar, Gajinder Pal Singh, Jennifer Gudeman
SLEEP Advances. 202414 CitationsOPEN ACCESS
Evidence of Accidental Dosing Errors with Immediate-Release Sodium Oxybate: Data from the US Food and Drug Administration Adverse Event Reporting System
Jennifer Gudeman, Danielle Burroughs
Drugs - Real World Outcomes. 202313 CitationsOPEN ACCESS
Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial
Yves Dauvilliers, Thomas Roth, Richard Bogan, Michael J. Thorpy, Anne Marie Morse, Asim Roy, Jordan Dubow, Jennifer Gudeman
SLEEP. 202313 CitationsOPEN ACCESS
Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: Phase 1 study in healthy volunteers
Richard Bogan, Michael J. Thorpy, John W. Winkelman, Jordan Dubow, Jennifer Gudeman, David Seiden
Sleep Medicine. 202212 CitationsOPEN ACCESS
A Survey of People Living with Narcolepsy in the USA: Path to Diagnosis, Quality of Life, and Treatment Landscape from the Patient’s Perspective
Luis E. Ortiz, Anne Marie Morse, Lois E. Krahn, Maggie Lavender, Matthew Horsnell, Dianna Cronin, Beth Schneider, Jennifer Gudeman
CNS Drugs. 202511 CitationsOPEN ACCESS
Related on ScholarIQ
Momenta Pharmaceuticals (United States)
Institution
Demographic characteristics and comorbidities of patients with narcolepsy: a propensity-matched cohort study
Paper
Evidence of Accidental Dosing Errors with Immediate-Release Sodium Oxybate: Data from the US Food and Drug Administration Adverse Event Reporting System
Paper
Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial
Paper
Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: Phase 1 study in healthy volunteers
Paper
A Survey of People Living with Narcolepsy in the USA: Path to Diagnosis, Quality of Life, and Treatment Landscape from the Patient’s Perspective
Paper